Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Vyome Holdings, Inc. (HIND)
Company Research
Source: Business Wire
Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND) announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility.Additional details on this funding are as follows:All additional funds were raised on January 27, 2026.1,089,045 common shares were sold at an average price of $5.00.This sales price represents a 59.2% premium to the prior day’s per-share closing price of $3.11.Net proceeds to the Company were approximately $5.29 million.The total dilution to existing shareholders as a result of this funding re
Show less
Read more
Impact Snapshot
Event Time:
HIND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIND alerts
High impacting Vyome Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
HIND
News
- Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 MonthsBusiness Wire
- Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 StudyBusiness Wire
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
HIND
Sec Filings
- 1/28/26 - Form 8-K
- 12/23/25 - Form 8-K
- 11/26/25 - Form 424B3
- HIND's page on the SEC website